Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements
Date:2/16/2010

CRANBURY, N.J., Feb. 16 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced financial results for the fourth quarter and full year 2009.  The Company also provided an update on advancements in its product pipeline related to its key strategic priorities for 2010.  Additionally, the Company stated that it believes it is well positioned to achieve its key milestone of completing enrollment for its Phase 3 study of Amigal (migalastat HCl) to support approval in the U.S. (Study 011) by year end.

Fourth Quarter and Full-Year 2009 Financials Summary

Amicus announced net income attributable to common stockholders of $1.45 per share for the three months ended December 31, 2009. For the year ended December 31, 2009, the net loss attributable to common stockholders was $0.29 per share. As of December 31, 2009, cash, cash equivalents, and marketable securities totaled $78.2 million.

John F. Crowley, Chairman and CEO of Amicus Therapeutics stated, "We are very pleased with the significant progress we made advancing Amigal into Phase 3 in 2009, and we expect to continue this momentum in 2010.  We are confident in the likelihood of success for Amigal and are excited we have the potential to bring to market the first oral treatment to patients with Fabry disease."  

Key Strategic Priorities

The Company reaffirmed its three key strategic priorities for 2010: Phase 3 development of migalastat HCl for Fabry disease, advancing chaperone-ERT combina
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... BELMONT, Calif. , July 21, 2014 /PRNewswire/ ... world,s first fluid-based accommodating intraocular lens, today announced ... Allen, Mosbacher, and Law Chair of Ophthalmology, and ... has joined the company,s Scientific Advisory Board. ... honors, including the American Academy of Ophthalmology Lifetime ...
(Date:7/21/2014)... July 21, 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, announced today that it will host a ... to discuss results for the period ended June 30, ... with respect to its clinical program for aramchol. ...
(Date:7/21/2014)...   Aventura , the leader for instant-on ... that MemorialCare Health System , a top ... at the Orange Coast Memorial Medical Center ... Orange Coast Memorial is a 218-bed general medical ... annually. The Aventura Roaming Aware Desktop (RAD) – ...
Breaking Medicine Technology:PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 2PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 3PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 4Galmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014 2MemorialCare Health System Launches Aventura at Orange Coast Memorial Medical Center 2MemorialCare Health System Launches Aventura at Orange Coast Memorial Medical Center 3MemorialCare Health System Launches Aventura at Orange Coast Memorial Medical Center 4
... 2007 - Cougar Biotechnology,Inc. (OTCBB:CGRB) today announced that ... Company's prostate cancer drug candidate CB7630,(abiraterone acetate) were ... Conference, which is currently taking place,in Lugano, Switzerland. ... presentations on Sunday, July 8, as part of ...
... Factor Xa Inhibitor,Shows a Significant Reduction in ... Enoxaparin with Similarly Low Bleeding,Rates , GENEVA, ... clinical trial,data presented today at the XXI ... demonstrate that once-daily,rivaroxaban (Xarelto®) achieved superior efficacy ...
Cached Medicine Technology:Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 5Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 6Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5
(Date:7/22/2014)... Hill, South Carolina (PRWEB) July 22, 2014 ... weight loss solution managed to lose 20 pounds. Unfortunately, the ... shaky and nauseated for the duration of her time using ... ‘manic’. One woman experienced heart flutters and insomnia as a ... woman experienced a heart attack at the age of 37 ...
(Date:7/22/2014)... Washington, DC (PRWEB) July 22, 2014 ... pleased to announce the release of Specialty Pharmacy ... the annual book that provides a comprehensive overview of ... year’s update includes management strategies and tactics for:, ... the ensuing cost and utilization concerns — including details ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Cumberland ... providing a dental experience that values anxiety-free dental care ... is essential for a child's dental care. , ... standard of care to infants, adolescents, adults and those ... emotional or physical disability, or require unique care, such ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 NOVAtime ... of enterprise Time and Attendance / Workforce Management ... a NOVAtime 3000 customer since 2007, has upgraded ... version of NOVAtime’s state-of-the-art, web-based time and attendance ... in Iowa (LSI) is a human services agency ...
(Date:7/22/2014)... CareTouch Communications, Inc. has formed a ... Community . CareTouch employees will select causes they are ... in line with their mission to help people in ... first cause is Hike for Hospice, to benefit the ... September 14, the CareTouch in the Community team will ...
Breaking Medicine News(10 mins):Health News:SlimPlate System Urge Women to Shun Controversial Weight Loss Pills for Healthier Methods Like Portion Control 2Health News:Latest Edition of Annual Book Provides Comprehensive Overview of the Specialty Pharmacy Arena 2Health News:Cumberland Pediatric Dentistry and Orthodontics of Clarksville Welcomes Dr. Peter Wojtkiewicz, Pediatric Orthodontist 2Health News:Cumberland Pediatric Dentistry and Orthodontics of Clarksville Welcomes Dr. Peter Wojtkiewicz, Pediatric Orthodontist 3Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 2Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 3Health News:CareTouch is a Peak Sponsor for the 9th Annual Hike for Hospice in Morrison, Colorado 2
... less healthy than their English counterparts, but they live as long ... study by researchers from the RAND Corporation and the Institute for ... 55 to 64 have higher rates of chronic diseases than ... And Americans age 65 and older -- while still sicker than ...
... PITTSBURGH, Nov. 3 Medicare patients in regions that spend ... quality care, according to a new study of spending practices ... (GSPH). The findings, published in the Nov. 3 Online First ... reveal great variation across the country in both drug spending ...
... A drug commonly used in Japan and Korea to treat ... cells traditionally resistant to chemotherapy, according to a new study led ... drug approved for use in Japan and South Korea, and not ... more than two decades to treat asthma and other allergic disorders ...
... and the Cincinnati Veterans Affairs (VA) Medical Center have found ... prescribed therapies for high blood pressure do not often adhere ... 2 online edition of the American Journal of Nephrology ... the Cincinnati VA, showed that treatment of hypertension in patients ...
... Goodwin HealthDay Reporter , WEDNESDAY, Nov. 3 (HealthDay ... with autism have a "disconnect" between their frontal lobe and ... show. The disconnect may help explain some ... autism, researchers report in the Nov. 3 issue of ...
... that older adults who wear multifocal contact lenses to ... that increases with age, may have greater difficulty driving ... problems with near vision, medically termed presbyopia, usually occurs ... inability to focus on objects up close. According ...
Cached Medicine News:Health News:Americans less healthy than English, but live as long or longer, study finds 2Health News:Americans less healthy than English, but live as long or longer, study finds 3Health News:Higher medication spending doesn't indicate better prescribing quality 2Health News:Medication adherence improves blood pressure control in chronic kidney disease 2Health News:Gene Associated With Autism May Alter How Brain Functions 2Health News:Gene Associated With Autism May Alter How Brain Functions 3Health News:Multifocal contact lenses may reduce vision for night driving 2
... contain a buffered sodium citrate ... a citrate concentration of 0.109 ... (3.8%). The mixing ratio is ... 9 parts blood. In addition ...
... Cross-match tubes are available ... serum tube contains a clotting ... cross-match tests where serum is ... EDTA cross-match tube is suitable ...
Inquire...
... EDTA K2 or EDTA K3 tubes. ... therefore blocks the coagulation cascade. Erythrocytes, ... anticoagulated blood sample are stable for ... are for the examination of whole ...
Medicine Products: